Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.

Blood advances - 27 Jan 2026

Dyer Michael R, Zheleznyak Alex, Teubner Erin N, Prior Julie L, Manion Brad, Jing Zhenghan, Sharma Amit K, Du Junwei, Tang Rui, Fiala Mark A, DiPersio John F, Veis Deborah, O'Neal Julie, Berezin Mikhail Y, Shokeen Monica

Abstract excerpt

ABSTRACT: Multiple myeloma (MM) is a plasma cell malignancy characterized by bone pain and end-organ failure. A major challenge in treating MM is therapeutic resistance. CD38-targeted immunotherapies, such as daratumumab, have significantly improved outcomes; however, variable responses, resistance, and relapse remain vital challenges. We hypothesized that loss of CD38 drives a more aggressive phenotype and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Membrane Glycoproteins

Share to Mice, Knockout

Share to Multiple Myeloma

Share to Tumor Microenvironment

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41056513
DOI: 10.1182/bloodadvances.2025017296
PMCID: PMC12828765

Genes

CD38

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.PMID 41056513Read ↗

A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stagesSemantic proximity Read ↗

CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myelomaSemantic proximity Read ↗

Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profilingSemantic proximity Read ↗

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read ↗

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myelomaSemantic proximity Read ↗

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.Semantic proximity Read ↗

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.Semantic proximity Read ↗

Molecular pathogenesis of multiple myeloma and its premalignant precursorSemantic proximity Read ↗

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.Semantic proximity Read ↗

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor MicroenvironmentSemantic proximity Read ↗

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.